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L E T T E R  T O  T H E  E D I T O R
The time has come to look for metabolic dysfunction-
associated fatty liver disease in adult patients with type 1 
Gaucher disease
Dear Editors,
We thank Starosta and colleagues for allowing us to clarify some 
peculiar aspects of metabolic dysfunction-associated fatty liver dis-
ease (MAFLD) in type 1 Gaucher disease (GD1).1,2
MAFLD encompasses a broad spectrum of histological lesions 
spanning steatosis, ballooning and inflammation with/without fi-
brosis. We agree that steatosis with necro-inflammation, featuring 
steatohepatitis, more likely progresses to clinically significant liver 
fibrosis than histological ‘simple’ steatosis. However, according to 
current guidelines, the screening approach for MAFLD in at-risk 
populations and the diagnostic work-up in patients with suspected 
MAFLD should start with non-invasive evaluation of steatosis, fol-
lowed by non-invasive assessment of fibrosis. While steatosis and 
fibrosis could be evaluated by non-invasive techniques, steatohepa-
titis diagnosis still exclusively relies on liver biopsy, that is unsuitable 
for screening purposes and is reserved for cases with suspicion of 
significant disease.3,4
The primary objective of our study was to verify if GD1 adults 
could be a population at risk of MAFLD by evaluating prevalence 
of and risk factors associated with steatosis. By showing that 40% 
of GD1 adults have non-invasive evidence of liver steatosis that is 
associated with features of metabolic syndrome (and not with GD1-
related variables), we think that our results do demonstrate that sta-
ble GD1 patients are a population worthy to be screened for the 
presence of MAFLD.1
The assessment of liver disease severity in such a population is 
another aspect that deserves attention. In our studies we showed 
that liver fibrosis is common in GD1 adults (19%) and is significantly 
associated with metabolic risk factors and steatosis.1,5 Consequently, 
we speculated that MAFLD may be an overlooked contributor of sig-
nificant liver disease in stable GD1 patients. We recognize that the 
peculiar metabolic abnormalities associated with GD1 itself, and only 
partially reverted by GD1 treatment, may participate in predisposing 
GD1 patients to liver disease progression. Moreover, we agree that 
only liver biopsy is able to definitely stage liver disease severity and 
to determine if steatohepatitis is the underlying histological feature 
of liver disease progression in these patients. Further studies are 
eagerly awaited to resolve these issues. In the meanwhile, far from 
wanting to oversimplify the complexity of liver disease in GD1 and 
to prove causality, we think that the main messages from our studies 
are that GD1 patients, even if properly treated for their inherited 
disease, should be closely monitored for the development of meta-
bolic risk factors, liver steatosis and fibrosis, and actively educated 
to healthy lifestyles.
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